Status:
COMPLETED
Atomized Intranasal Vs Intravenous Ketorolac in Acute Renal Colic Pain Management.
Lead Sponsor:
Oman Medical Speciality Board
Conditions:
Acute Renal Colic
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
PHASE3
Brief Summary
Introduction: Pain is a common reason for individuals to seek health care, especially emergency care. Ketorolac has numerous advantages over other pain medications, especially the opioids. The intrana...
Detailed Description
Research objectives and hypothesis: The aim of this study is to compare the analgesic effects of intranasal Ketorolac tromethamine versus intravenous Ketorolac tromethamine in adult patients with mod...
Eligibility Criteria
Inclusion
- Patient with classical acute renal colic symptoms.
- Age ≥ 18 years and \< 65 years
- Stable patient with stable vital signs.
- Mentally competent patient who can understand and sign the consent form.
- Pain score is moderate to severe (visual analog scale 7 or more).
Exclusion
- Patients who are allergic to ketorolac.
- Patients with active peptic ulcer disease.
- Patients with a history of asthma, urticaria, or other allergic-type reactions after taking NSAIDs.
- Patients with renal disease and renal transplant.
- Patients who are at risk for renal failure due to volume depletion.
- Pregnant or nursing mothers.
- Patients with any other contraindication to the use of ketorolac, or in whom the use of ketorolac would not be consistent with the approved package insert.
Key Trial Info
Start Date :
December 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT04441762
Start Date
December 30 2020
End Date
February 1 2022
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sultan Qaboos University Hospital
Muscat, Aseeb, Oman, 123